接受生物制剂治疗患者接种AS04C佐剂乙型肝炎疫苗的免疫原性
该回顾性观察性队列研究纳入2016年1月至2018年9月期间301例接受生物制剂治疗的18岁以上患者,按0-1-2-6月程序接种4剂AS04C佐剂乙型肝炎疫苗(Fendrix®)。基础接种后血清转化率为82.1%(95%CI 77.6-86.6),无应答者加强接种后达89.0%(95%CI 85.3-92.7);使用糖皮质激素及其高剂量、年龄超过60岁及主要诊断与较低血清转化率和较低抗-HBs滴度相关。
要点
- 301例生物制剂治疗患者接种4剂AS04C佐剂乙肝疫苗,基础免疫后血清转化率82.1%(95%CI 77.6-86.6)。
- 无应答者加强接种后血清转化率达89.0%(95%CI 85.3-92.7)。
- 糖皮质激素使用及其高剂量、年龄超过60岁和主要诊断与较低血清转化率及较低抗-HBs滴度相关。
核心结论
- AS04C佐剂乙型肝炎疫苗(Fendrix®)在自身免疫性疾病并接受免疫抑制和/或免疫调节治疗的患者中产生 adequate 免疫应答。
- 作者提出该免疫程序可作为接受积极生物制剂治疗的自身免疫性疾病患者保护的一种非常合适且适配的选择。
研究设计与样本
- 分析性观察性回顾性队列研究,于2016年1月至2018年9月进行。
- 纳入301例接受生物制剂治疗的18岁以上患者,接种4剂AS04C佐剂乙型肝炎疫苗(Fendrix®),按0-1-2-6月免疫程序。
- 评估社会人口学、临床和药理学变量,结局变量为抗-HBs抗体滴度,并计算滴度几何均值(GMT)作为集中趋势指标。
主要发现
- 基础接种后82.1%(95%CI 77.6-86.6)的接种患者发生血清转化。
- 无应答者加强接种后血清转化率达89.0%(95%CI 85.3-92.7)。
- 使用糖皮质激素及其高剂量、年龄超过60岁和主要诊断与较低血清转化率和较低抗-HBs滴度相关。
临床怎么用
- 作者提出该免疫程序可作为接受积极生物制剂治疗的自身免疫性疾病患者保护的一种非常合适且适配的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B vaccination is necessary for patients with biologic therapies because of the immunomodulatory effect of these drugs. Due to the elevated use of these therapies in the latest years, the research for new vaccination regimens and the improvement of the current ones is essential. New adjuvants like AS04C might be a potential strategy to improve immune response. Hepatitis B vaccine adjuvanted with AS04C has not been studied in this population before. We analyzed the immunogenicity of an adjuvanted hepatitis B vaccine in patients with biologic therapies. Variables that might affect vaccine response were also evaluated. METHODS: Analytic observational retrospective cohort study performed between January 2016 and September 2018. 301 patients under biological treatment aged from 18 years were included. Patients received 4 doses of hepatitis B adjuvanted vaccine (Fendrix®) in a 0-1-2-6 month immunization schedule. Several sociodemographic, clinical and pharmacological variables were evaluated. The outcome variable was measured as the antibody titers (anti-HBs). The geometric mean of titers (GMT) as a measure for the central tendency was calculated from these values. RESULTS: The immunization schedule of the hepatitis B vaccine adjuvanted with AS04C demonstrated high levels of seroconversion with 82.1 % (95 % CI, 77.6-86.6) of vaccinated patients seroconverting after primary vaccination and achieving 89.0 % (95 % IC, 85.3-92.7) after the booster doses for non-responders. The use of corticosteroid therapy and high doses of them, age over 60 years and the main diagnosis were associated with lower seroconversion rates and lower anti-HBs titers. CONCLUSIONS: The hepatitis B vaccine adjuvanted with AS04C (Fendrix®) produces an adequate immune response in patients with autoimmune diseases and immunosuppressive and/or immunomodulating therapies. This immunization schedule is proposed as a very suitable and adapted option for the protection of patients with autoimmune diseases under active biological therapies.
引用
- María FP, María BA, Darío RO, et al. Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies. Vaccine. 2022. PMID: 36522266. doi:10.1016/j.vaccine.2022.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。